McKesson (MCK) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$411.0B

Revenue (quarter)

$105.4B

Revenue growth (year over year)

+7.72%

Gross profit (trailing twelve months)

$15.0B

Gross margin

3.64%

Net income (trailing twelve months)

$5.3B

Net income (quarter)

$1.0B

Net income growth (year over year)

+24.19%

Net margin

1.29%

Return on equity

—

EPS (trailing twelve months)

$37.44

Book value per share

−$14.32

P/E (trailing twelve months)

25.36

Price to book

—

Debt to assets

101.47%

Payout ratio

8.24%

Dividend yield

0.35%

Company profile

McKesson is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

• Is McKesson (MCK) profitable?

  Yes. McKesson earned $5.3B in net income over the trailing twelve months, a net margin of 1.29%.

• How much revenue does McKesson (MCK) make?

  McKesson generated $411.0B in revenue over the trailing twelve months, up 7.72% year over year.

• What is MCK's P/E ratio?

  McKesson trades at 25.4 times trailing twelve-month earnings, on an EPS of $37.44.

• How do I buy stock in McKesson (MCK)?

  MCK trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.